Stock prices for Ambit Biosciences and Emergent BioSolutions dipped after abstracts for their data presentations at the upcoming American Society of Hematologists (ASH) Annual Meeting and Exposition became public on 7 November, and GlycoMimetics postponed its initial public offering on 8 November, but all three companies have data worth watching when ASH welcomes doctors and scientists to New Orleans from 7 to 10 December.
Data showing significant reductions in the use of opioid pain relievers and length of hospital stays for GlycoMimetics's lead drug...